Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC Meeting Abstract
| Authors: | Burns, T. F.; Dragnev, K.; Fujiwara, Y.; Murciano-Goroff, Y. R.; Lee, D. H.; Hollebecque, A.; Koyama, T.; Cassier, P.; Italiano, A.; Heist, R. S.; Han, J. Y.; Deming, D.; Spira, A.; Sabari, J.; Chisamore, M. J.; Fink, A.; Chen, A.; Willard, M. D.; Oxnard, G. R.; Ammakkanavar, N. R.; Pruthi, A. |
| Abstract Title: | Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC |
| Meeting Title: | 51st Annual Scientific Meeting of the Clinical Oncology Society of Australia (COSA) |
| Journal Title: | Asia-Pacific Journal of Clinical Oncology |
| Volume: | 20 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2024 Nov 13-15 |
| Meeting Location: | Gold Coast, Australia |
| ISSN: | 1743-7555 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2024-11-01 |
| Start Page: | 137 |
| End Page: | 138 |
| Language: | English |
| ACCESSION: | WOS:001352150600187 |
| PROVIDER: | wos |
| DOI: | 10.1111/ajco.14117 |
| Notes: | Meeting Abstract: 258 -- This meeting abstract was published under the "Poster Abstracts" section of the issue -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work